Podcasts about neuroscience center

Are you constantly on your phone or computer? Find out how it could affect your health and what you can do about it from Dr. Clifford Solomon, director of the Spine and Neuroscience Center at UM Baltimore Washington Medical Center and a member of the UM Spine Network.

We're going to do something a little different today. I've always been fascinated with the origin stories and journey to content creator or influencers of those that I meet along the way. I've met and interviewed dozens who sat out be social media famous and monetize their content. I've talked to many who fell into by accident.  But the constant thread in all those journeys is their stories are fascinating to me. A couple of weeks ago, I came across a local content creator, influencer and podcaster here in Louisville, honestly by happenstance. I knew who she was, of course. I like to keep my eye on who is creating content in my backyard. But she and I hadn't had reason to make a more one-to-one connection. Until we did. Rosa Hart runs LouReview.com. The cornerstone content there is the Lou Review Podcast. She has the obligatory social media channels, too. She mostly reviews restaurants around town, but also shares more broad experiences with events, attractions and the like.  My team at CIPIO.ai put her on a list of creators matched up with one of our clients. We reached out and were moving through the agreement and deliverables when Rosa decided she didn't want to connect her channels to our platform. Just didn't know who CIPIO was and whether or not connecting her social channels to a company like that was a good idea. My team let me know and I reached to introduce myself more formally and reassure her that we use that connection just to make measurement easy for everyone, we're a trusted partner and I'm literally a 10 minute drive up the road so you can come ring my neck if we ever do you wrong. Rosa … invited me to her house. So I went. And probably heard several of the most interesting explanations of a content creator's origin story, motivations and journeys I've ever heard. And, as a bonus, Rosa's now three-year journey as a content creator has opened up a surprising and awesome new project that brings her day job and her passion together.  That project is Strong After Stroke, a new offering from Norton Healthcare in Louisville. Rosa's day job is a stroke after care nurse for Norton's Neuroscience Center. The new show launches the very day this episode dropped. You can find it on YouTube as well. Today on Winfluence, I'm going to take you with me to meet Rosa Hart. This isn't a virtual interview. We're going to her house. We'll meet her dog. Her daughter's cartoons will play faintly in the background.  Today's Winfluence is an audio journey. Come along for the ride.  This very special episode of Winfluence is presented by CIPIO.ai where you can create a consistent flow of authentic user-generated content to fuel paid, earned, shared and owned campaigns that set your content marketing on fire! One of the main methods of doing that is by shifting your influencer marketing focus to a Community Influence Marketing one. That's where you discover the influential voices in your own community of customers, fans and followers, and partner with them to create authentic content that recommends your brand.  Download CIPIO.ai's new ebook called The Marketer's Guide to Community Influence Marketing. It's a step-by-step manual that shows you how to do it. The result is a more cost-efficient way to engage creators and drive word-of-mouth marketing while capturing better-performing content for your paid and owned social media efforts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Between 3 and 5% of the people living with MS are diagnosed before their sixteenth birthday. In many respects, pediatric MS is just like MS in adults. But it carries with it a distinct set of what I call social complications that can feel even more challenging to navigate than MS itself. Just think back to the awkwardness of your pre-teen and teenage years. The pressures of school, friends, and dating are a lot for any kid to contend with. And that's without having to think about living with a chronic disease like multiple sclerosis. Joining me for what I consider to be a masterclass in pediatric MS is Dr. Brenda Banwell. Dr. Banwell is Chief of the Division of Neurology and Co-Director of the Neuroscience Center at Children's Hospital of Philadelphia, and one of the foremost experts on pediatric MS in the world. We're also sharing the details of very encouraging research that sheds new light, as well as provides new evidence, about primary progressive MS, suggesting a new pathway for future treatments. We'll tell you about Healthy Aging in MS, the new clinical and research initiative at the University of Texas at Austin Dell Medical School. And we'll share what the latest research is telling us when it comes to answering the question, "Should you discontinue your disease-modifying therapy once you turn 60?" We have a lot to talk about! Are you ready for RealTalk MS??! This Week: It's a masterclass in pediatric MS  :22 Researchers take a major step forward in understanding and potentially treating primary progressive MS  2:01 University of Texas at Austin Dell Medical School launches Healthy Aging in MS initiative  6:49 Is it safe to stop your disease-modifying therapy as you age? Here's what the latest research is telling us  8:58 Dr. Brenda Banwell takes us on a deep dive into pediatric-onset MS  13:05 Share this episode  37:05 Have you downloaded the free RealTalk MS app?  37:25 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/285 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com STUDY:  Cerebrospinal Fluid Immunoglobulins in Primary Progressive Multiple Sclerosis are Pathogenic https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awad031/7024973 STUDY: Discontinuation of Disease-Modifying Therapy in MS Patients Over 60 Years Old and Its Impact on Relapse Rate and Disease Progression https://sciencedirect.com/science/article/abs/pii/S0303846723000288 RealTalk MS Episode 255: Aging with MS with Dr. John Corboy https://realtalkms.com/255 PEDIATRIC MS RESOURCES: National MS Society Information and Resources on Pediatric MS https://nationalmssociety.org/pediatricms Oscar the MS Monkey In-Person Camp and Retreats for Kids with MS and Their Families https://mroscarmonkey.org Network of Pediatric Multiple Sclerosis Centers https://usnpmsc.org iConquer MS Kids & Teens https://kidsandteens.iconquerms.org/kidsandteens Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 285 Guest: Dr. Brenda Banwell Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a number of experts in the clinical care of MS who were in attendance at the 2022 ECTRIMS Congress, including Darin T. Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center; Federica Picariello, PhD, a health psychologist and postgraduate research associate at King's College London; Brenda Banwell, MD, chief of the Division of Neurology and codirector of the Neuroscience Center at the Children's Hospital of Philadelphia; Riley Bove, MD, associate professor of neurology, University of California, San Francisco; Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research Unit at the University of Melbourne, and head of the MS Centre at the Royal Melbourne Hospital; and Marisa McGinley, DO, a neurologist at the Mellen Center for MS at Cleveland Clinic. Click here for more coverage of ECTRIMS 2022. Episode Breakdown: 1:15 – Darin Okuda, MD, on the implications of the ARISE data in RIS 5:50 – Federica Picariello, PhD, on addressing fatigue and its mechanisms 10:40 – Brenda Banwell, MD, on advances in pediatric-onset MS 16:05 – Riley Bove, MD, on treatment NMOSD in pregnancy and post partum 21:30 – Tomas Kalincik, MD, PhD, on stem cell transplantation in MS 27:00 – Marisa McGinley, DO, on the optimal experience of teleneurology This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome Alyssa Dver to The TufFish Show, a place to help writers and aspiring authors get out of their own way to leave a legacy by telling the stories they want to share through writing their own books and confidently sharing them with others. The writing process can be tough and the business side can feel scary, but TufFish makes both feel smoother and achievable. Visit https://www.jennifermilius.com/tuffish to learn more. As you pursue your goal of being an author and running an author business, there will be times when you face one of the three Fs - fear of failure, fear of rejection, or fear of regret. Yet what's important is what you do next when you recognize it's happening, and this conversation with Alyssa is full of so much wisdom to not only understand what's happening, but how to move through it successfully. Confidence Crusader, Neuro Nerd and Success Equalizer, Alyssa leads the American Confidence Institute, that has empowered over 350,000 people at organizations including the US Air Force, US Tennis Association, Spotify, Wayfair, Panera, Amazon, Dell, Staples, UPenn's Innovation Center and dozens more. Supporting her mission to bring more confidence to the world, Alyssa is the Confidence Educator for IT Cosmetics, a global L'Oréal brand. She's a 2-time TEDx speaker, hosts the podcast Real Confidence and contributes to Thrive Global and many other online media. Her 7th book, Confidence is a Choice: Real Science. Superhero Impact., was recognized by the International Book Awards and endorsed by experts at Harvard Medical School, Wharton's Neuroscience Center, MIT's Trust Center, Yale's Office of Diversity, UC Berkeley Executive Education, and other top academic and business leaders. With a commitment to make workplace diversity, equity and inclusion a reality, Alyssa founded and chairs the ERG Leadership Alliance, the largest association training employee group leaders, executive sponsors and allies. In 2021, Alyssa received a Stevie award for Achievement in Thought Leadership. What fuels her confidence? Her unusually patient husband, 2 very tall sons, and their quirky, but really cute, rescue pooch. Visit - www.AmericanConfidenceInstitute.com Book purchase links: Alyssa Dver's books

When we're confronted with a challenging task, we reassure ourselves it's probably achievable by saying, “Well, it's not brain surgery.” We say this because every single thing created by humans – from the sewer system to satellites - ultimately came from the human brain. And yet how the brain works remains among the most vexing and mysterious elements of our existence. Of course, not all humans are created equal. There is a small group of men and women for whom the human brain is not a complete mystery. These folks devote their professional lives to understanding and unravelling its secrets. One of these neuroscientists lives and works in New Orleans. Dr. Nicolas Bazan is the founding director of the Neuroscience Center of Excellence at LSU's Health Sciences Center. He leads a team of 90 researchers in areas ranging from Parkinson's Disease to Traumatic Brain Injury. Dr Bazan's team publishes multiple research findings each year. And Dr Bazan himself is the holder of around 120 patents in the area of neuroscience and the treatment of neurological disorders. Notable even among all his other achievements in the field, Dr Bazan is the discoverer of a new class of biochemicals found in the brain, known as ELV's. In 2018, a year after he made this discovery, Dr. Bazan founded a local company, NeuResto Therapeutics, to research and develop the use of ELV's in the treatment of Traumatic Brain Injury and stroke. If you've ever been in the hospital, or have visited anyone who's a hospital patient, you'll be familiar with an IV. Typically, one of the first things that happens to you as a hospital patient - or even in an ambulance on the way to the hospital – is you get an IV line inserted into your arm or hand. The reason for that is, intra-venous – which is what IV stands for – it means basically straight-into-the-vein - is the most efficient method of delivering fluids or drugs to someone who needs them. But delivering drugs to a patient through an IV is not an exact science. It relies on a human operator getting it right. In light of that, here are some sobering statistics. Medical errors are reportedly the 3rd leading cause of death in the US, after heart disease and cancer. 73% of medication errors involve what's called “push doses.” A “push” is the rate that a person administers a drug through an IV. 95% of IV push errors are the result of the drug being administered too quickly. That's why Tonia Aiken has invented a device she calls SafePush - which is also the name of her company. SafePush, the device, is a small, disposable piece of equipment that fits on the tip of a syringe or an IV and precisely regulates the flow of a drug in a way that doesn't let the person administering the dose push it any faster than the set rate. SafePush, the company, was launched in 2019 and is looking at potential market of 137 million devices per year. The cost of the device is $20 - about the same as a large pizza. 137 million-times-twenty is a lot of pizza. At some point we're going to have recalibrate how we think about and describe New Orleans. As well as describing ourselves as the home of Mardi Gras and the Hurricane, we could equally legitimately call ourselves something like, “world leader in medicine and medical technology.” Nicolas Bazan and Tonia Aiken enjoy Mardi Gras and cocktails as much as the rest of us (Tonia was Queen of Krewe du Vieux!), but they're giving us a whole other reason to be proud of living here. Out to Lunch is recorded live over lunch at NOLA Pizza in the NOLA Brewing Taproom. You can find photos from this show by Jill Lafleur at itsneworleans.com.  See omnystudio.com/listener for privacy information.

We have an amazing Grand Rounds follow up interview for you today! Dr. Diogo Haussen, Director of Neuroendovascular Service at the Marcus Stroke & Neuroscience Center at Grady Memorial Hospital joined us for a Grand Rounds presentation with medical students and faculty at McGovern Medical School. His presentation was titled, Carotid Webs: Armed and Dangerous. Our Senior Neurology Resident, and future UT Stroke Fellow, Mohammad Ahmad, interviewed Dr. Haussen following his presentation to ask some more in depth questions. As with our previous Grand Rounds episode, we added the Q&A from the live Grand Rounds because it added so much value to this episode. __________ The Institute for Stroke and Cerebrovascular Disease (UTHealth Stroke Institute) http://www.utstrokeinstitute.com/ Host: Mohammad Ahmad, Neurology Resident, UTHealth Houston Guest: Dr. Diogo Haussen | https://www.gradyhealth.org/doctors/diogo-haussen Twitter: @UTHealthStroke Instagram: @UTHealthStroke Facebook: facebook.com/uthealthstroke Ideas and opinions are our own and this podcast is not a substitute for expert medical advice. About StrokeBusters is a podcast series of recorded conversations on the topic of stroke and cerebrovascular disease. Based in the Texas Medical Center, the largest medical center in the world, we tap into our local network of astonishing leaders in healthcare and medicine to discuss the latest and most exciting news on stroke. Throughout this ten-episode series, we connect with UTHealth physicians and researchers, many of who are experts in their field, to discuss their practice, cutting-edge research, and medical care. Who We Are The Institute for Stroke and Cerebrovascular Disease, better known as the Stroke Institute, serves as a multi-disciplinary hub for research and best practices in stroke recovery, stroke prevention, services, population health, and vascular dementia. We are one of the most active research and clinical programs in the country, the first Comprehensive Stroke Center in the state, and launched the first Mobile Stroke Unit in the nation. Our stroke program, founded by Dr. James Grotta in 1979, specializes in stroke epidemiology, clinical trial design, and basic science. We train the next generation of revolutionary academics and leaders in cerebrovascular disease through our NINDS-funded fellowship programs. Contact For more information or if you have any questions, please contact us at info.uthiscd@gma

Riz Hatton talks about what's new in the Spine and Orthopedic industry.

Riz Hatton talks about what's new in the Spine and Orthopedic industry.

Our conversation today was gave us great information about detecting, responding and treating strokes and aneurysms. It is part of our community health partnership with Valley Health where we talk each month with administrators, physicians, and other Valley Health staff about health topics, events, and the community. Joining me today was Dr. Habibullah Ziayee, a fellowship-trained interventional neurologist with advanced expertise in the minimally invasive treatment of acute ischemic stroke and brain aneurysm. Dr. Ziayee recently joined the medical staff of Winchester Neurological Consultants | Valley Health and provides care at Winchester Medical Center. Dr. Ziayee first explained the additional experience & insight that comes with being fellowship-trained. He also walked us through the field of neurology and what role and interventional neurologist plays. We then discussed his work with strokes & brain aneurysms. We talked about the critical importance of reacting quickly to a potential stroke and the acronym BE FAST: B: Balance. Sudden loss of balance. E: Eyes. Blurred, double vision or loss of vision in one or both eyes. F: Face drooping or numb on one side. A: Arm weakness or numbness on one side.   S: Speech that is slurred, hard to understand or the inability to speak. T: Time. Call 911 immediately for any of these symptoms, even if they go away. He explained the different types of treatment and how far both surgery and imaging have come to increase the likelihood of full recoveries for stroke patients. Learn more about the Neuroscience Center at Valley Health by clicking here.

Riz Hattton shares the latest news on the Spine and Orthopedic industry.

Dr. Rishav Koirala is a Psychiatrist who is pursuing a Ph.D. from of University of Oslo, Norway. He is the Executive Director at Brain and Neuroscience Center, Nepal. In this Podcast on Mental Health, Dr. Rishav Koirala talks about Resilience, Mental Illnesses, Anxiety, Depression, how one needs to be treated, and much more. Dr. Rishav Koirala's LinkedIn: https://www.linkedin.com/in/rishav-koirala-1940abb9/ MHRN Website: http://www.mhrnepal.org/ You can Reach out to Dr. Rishav Koirala at: rishavk@gmail.com

Teachers prepare for changes after Florida lawmakers pass controversial new education laws. We'll learn about a new research facility coming to south Florida that focuses on neurological conditions. Plus, we say goodbye to a beloved local bookstore that has focused on bringing joy to mystery lovers since the mid-90s.

On November 11, 2021, we welcomed Jason Stein to discuss genetics, causality, brain organoid models, and large scale studies of the genetics of brain structure and disease. Dr. Stein is Associate Professor Dept. Genetics and Neuroscience Center, University of North Carolina School of Medicine https://www.steinlab.org/ Joining us: Melanie Carless, Department of Neuroscience, Developmental and Regenerative Biology, UTSA Host: Salma Quraishi, Department of Neuroscience, Developmental and Regenerative Biology, UTSA

On November 11, 2021, We welcomed Jason Stein to discuss genetics, causality, brain organoid models, and large scale studies of the genetics of brain structure and disease.Dr. Stein is Associate Professor Dept. Genetics and Neuroscience Center, University of North Carolina School of Medicinehttps://www.steinlab.org/Joining us: Melanie Carless, Department of Neuroscience, Developmental and Regenerative Biology, UTSAHost:Salma Quraishi, Department of Neuroscience, Developmental and Regenerative Biology, UTSA https://neuroscience.utsa.edu​Neuroscientists Talk Shop podcast: https://tinyurl.com/yxatz6fq​UTSA Neurosciences Institute: https://neuroscience.utsa.edu​The University of Texas San Antonio: https://www.utsa.edu​

On Episode 7 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the August 2021 issue of Stroke: “Stroke Risks in Adult Survivors of Preterm Birth: National Cohort and Cosibling Study” and “Roles of Phytoestrogen in the Pathophysiology of Intracranial Aneurysm.” She also interviews Drs. Nirav Bhatt and Diogo Haussen about their article “Reliability of Field Assessment Stroke Triage for Emergency Destination Scale Use by Paramedics: Mobile Stroke Unit First-Year Experience.” Dr. Negar Asdaghi: 1) Can preterm birth be associated with increased risk of stroke in adulthood? 2) Can a plant-based diet high in phytoestrogens reduce the risk of aneurysm formation and aneurysmal rupture in postmenopausal women? 3) What is the predictive ability of FAST-ED score in detection of large vessel occlusion? We will review these questions in today's podcast. You're listening to the Stroke Alert Podcast. Stay with us. Dr. Negar Asdaghi:         From the Editorial Board of Stroke, welcome to the Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. The August 2021 issue of Stroke covers a wide range of topics from examining if the presence of spot sign modifies the treatment effect of tranexamic acid in patients with intracerebral hemorrhage to the results of the PRESERVE randomized clinical trial examining whether intensive blood pressure lowering in patients with severe cerebral small vessel disease can be associated with progression of white matter damage as detected by diffusion tensor imaging or MRI studies, which I encourage you to review in addition to our podcast today. Dr. Negar Asdaghi:         Later in today's podcast, I have the pleasure of interviewing Drs. Diogo Haussen and Nirav Bhatt from Emory University on their work on reliability of FAST-ED scale when used by the paramedics in mobile stroke units and learn about the implementation of mobile stroke units in Atlanta. But first with these two articles. Dr. Negar Asdaghi:         Preterm birth, defined as birth prior to 37 weeks of gestation, affects approximately 11% of births worldwide. Today, with the advent of modern neonatal and pediatric care, the majority of preterm babies survive into adulthood. Multiple studies have shown that adult survivors of preterm birth are at increased risk of developing vascular risk factors, such as diabetes and hypertension, and have a higher incidence of ischemic heart disease as compared to their age-matched individuals born at term, though the association between preterm birth and risk of stroke is not well studied. Dr. Negar Asdaghi:         In the current issue of the journal, Dr. Casey Crump from Departments of Family Medicine and Community Health and Population Health Science and Policy at Icahn School of Medicine, Mount Sinai, New York, examined whether preterm birth is associated with an increased risk of stroke and its major subtypes in adulthood. The authors use the prenatal and birth information obtained from the Swedish Birth Register, which contains information for nearly all births in Sweden since 1973. The study cohort included over 2,200,000 singleton live births in Sweden from 1973 to 1994. These years were chosen to allow for sufficient follow-up into adulthood. The study cohort was examined for the earliest diagnosis of stroke from the time the participants turned 18 through September 31, 2015, and the maximum age of included population is 43 years. Stroke was identified using ICD codes from all primary and secondary diagnosis in the Swedish Hospital and Outpatient Registries and all deaths attributed to stroke in the Swedish Death Register. Dr. Negar Asdaghi:         Cosibling analyses assess for potential shared, familial confounding factors, such as genetic and environmental factors, that could contribute to development of stroke. In 28 million person-years of follow-up, 4861, or 0.2% persons, were diagnosed with stroke between 18 to 43 years of age. The authors found that low gestational age at birth was associated with a significantly higher risk of first-time stroke in adulthood. In their adjusted model, as compared to those born at full-term, the hazard ratio for any stroke associated with early preterm, that is birth between 22 to 33 weeks of gestation, was 1.4, and the hazard ratio for late preterm, that is birth between 34 to 36 weeks of gestation, was 1.22, both of which were statistically significant. Interestingly, each additional week of gestation was, on average, associated with a 3% lower risk of first stroke in adulthood. Dr. Negar Asdaghi:         Similar associations were found in men and women and for both hemorrhagic and ischemic strokes. These findings were only partially explained by shared genetic or environmental risks of preterm birth and stroke within families, suggesting important direct effects of preterm birth on risk of stroke. Multiple putative mechanisms that could potentially link preterm birth with increased stroke risk were discussed in the paper as well, including interaction of fetal angiogenesis during the critical developmental period leading to reduced capillary density and increased arterial stiffness, to persistently elevated levels of anti-angiogenic factors, which are correlated with increased blood pressure development and development of hypertension in adulthood. In summary, the study findings suggest that preterm birth should be recognized as a risk factor for stroke later in life, and survivors need early preventive evaluation and long-term clinical follow-up into adulthood to reduce their lifetime risk of stroke. Dr. Negar Asdaghi:         The incidences of intracranial aneurysm and aneurysmal subarachnoid hemorrhage are high in postmenopausal women, suggesting estrogen may be protective against aneurysm formation or aneurysmal rupture. However, estrogen-containing hormone replacement therapy is also associated with an increased risk of other significant adverse outcomes, such as increased risk of breast cancer and ischemic stroke, and is not routinely recommended for primary prevention of chronic conditions in postmenopausal women. Isoflavones, a type of phytoestrogen, are plant-based, diet-derived compounds with properties similar to estrogen. Two types of isoflavones, genistein and daidzein, are found in soybeans, chickpeas, and lentils and are thought to be the most potent phytoestrogens that exert estrogenic activities with tissue and receptor specificity. Regular consumption of isoflavones has been shown to alleviate the vasomotor symptoms of estrogen deficiency and associated with reduced incidence of estrogen-dependent diseases in postmenopausal women. Daidzein, once ingested, is converted to its bioactive metabolite, equol, which preferentially binds to estrogen receptor beta, a receptor subtype responsible for the protective effect of estrogen against the formation and rupture of intracranial aneurysms. Dr. Negar Asdaghi:         In the paper titled "Roles of Phytoestrogen in the Pathophysiology of Intracranial Aneurysm," Dr. Tomoki Hashimoto from the Barrow Aneurysm and AVM Research Center, Departments of Neurosurgery and Neurobiology, the Barrow Neurological Institute, and colleagues investigated whether the phytoestrogens daidzein and its bioactive form, equol, are protective against the formation and rupture of intracranial aneurysms in ovariectomized female mice. Intracranial aneurysms were induced by combining systemic hypertension and a single injection of elastase into the CSF at the right basal system. Ovariectomized mice were fed with an isoflavone-free diet. The systemic treatment with equol delivered via an implanted mini-osmotic pump in the treatment group (0.5 mg/kg/day) or vehicle (in the control group) began one week before aneurysm induction and was continued for four weeks thereafter. So, what they found was that equol treatment significantly reduced the incidence of aneurysm formation compared to vehicle, and there was a trend for equol-treated mice to have a lower incidence of aneurysmal rupture than control mice, while there was no difference in the blood pressure noted between the two groups. Dr. Negar Asdaghi:         Furthermore, systemic treatment through equol decreased mRNA expression of proinflammatory cytokines, such as IL-6 and interleukin-1β. Importantly, equol seems to require estrogen receptor beta, as the observed protected effects of equol against aneurysm formation was not duplicated in ovariectomized estrogen receptor beta knockout mice. The authors further demonstrated that dietary daidzein reduced the incidence of aneurysm formation, an effect that was dependent on the conversion of daidzein to equol as the beneficial effect of this dietary supplement was abolished in mice that were fed vancomycin, which prevented the intestinal microbial conversion of daidzein to equol. In summary, this study showed that both dietary oral daidzein or the systemic use of its bioactive metabolite, equol, protect against aneurysm formation in ovariectomized female mice through the activation of estrogen receptor beta and subsequent suppression of inflammation. These results indicate a potential therapeutic value of phytoestrogen in prevention of intracranial aneurysm formation and related subarachnoid hemorrhage. Dr. Negar Asdaghi:         Early recognition of stroke-like symptoms, combined with increased utilization of revascularization therapies, have greatly improved the clinical outcomes of patients with acute ischemic stroke, but have similarly resulted in an ever-growing demand on the stroke systems of care. In the era of endovascular thrombectomy, a prehospital scoring tool with predictive abilities for detection of a target vessel occlusion can greatly assist in the appropriate triage, transfer, and activation of the endovascular team for eligible patients, all the while preventing the inevitable fatigue that accompanies the overuse of the system by properly triaging out those who have a lower likelihood of needing endovascular therapy. For any scoring system used in the prehospital setting, the need for precision needs to be balanced with notions such as ease of administration, time consumption, and reproducibility, as decisions made in the field are invariably fast and frequently made in unstable situations. The Field Assessment Stroke Triage for Emergency Destination, or the FAST-ED scale, is one such stroke scale that meets many of the above-stated criteria in patients with stroke-like presentations to predict a possible large vessel occlusion. Dr. Negar Asdaghi:         In the paper titled "Reliability of FAST-ED Scale Use by Paramedics: Mobile Stroke Unit First-Year Experience," Drs. Nirav Bhatt and Diogo Haussen and colleagues, from the Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, and the Department of Neurology at Emory University School of Medicine in Atlanta, report on the reliability of the FAST-ED score in the prehospital setting when used by the paramedics in a mobile stroke unit. I'm joined now by Drs. Bhatt and Haussen to discuss this paper. Good afternoon, Nirav and Diogo. Thank you very much for joining us. Dr. Nirav Bhatt:               Thank you so much for the invitation. I'm very happy to be here. Dr. Diogo Haussen:         Thank you very much. It is a great pleasure to join you. Dr. Negar Asdaghi:         Right. In this paper, the FAST-ED score was administered by the paramedics in a mobile stroke unit. So Nirav, to get us started, please tell us about the concept of a mobile stroke unit, how long it's been implemented in Atlanta, and what it means for patients with stroke-like symptoms who would possibly have a large vessel occlusion. Dr. Nirav Bhatt:               The mobile stroke unit, or the MSU, is an ambulance equipped with a CT scanner and state-of-the-art telemedicine capabilities and is operated by the Grady Emergency Medical Services that covers majority of Metro Atlanta and many of its suburbs, caring for a population of a little over 500,000. It was specifically incorporated to expedite care amongst patients with suspected strokes and went into operations on 30th May, 2018, Monday through Saturday, 12 hours a day, 8 a.m. through 8 p.m. It is operated by a group consisting of an EMT driver, a paramedic, an emergency medicine registered nurse, and a CT technician. So, when a patient has symptoms suspicious for a stroke, the MSU is activated either through 911 dispatch or by an ALS ambulance crew evaluating a possible stroke alert patient in the field. After the initial stroke triage performed by the MSU crew, if there is a persistent suspicion for stroke, the patient is transferred to the MSU and a noncontrast CT scan of the brain is immediately performed. Dr. Nirav Bhatt:               These CT images are transmitted via the telemedicine platform and are available for review by the vascular neurologist and neuroradiologist in real time. With the help of telemedicine technology, a remotely located vascular neurologist then examines the patient. So, with the help of telemedicine and CT scanner, it allows the remotely located vascular neurologist to identify patients who may qualify for IV alteplase, which is then administered in the MSU to qualifying patients, and these patients get subsequently transported to a stroke treatment center. Now, if the neurological exam is concerning for a large vessel occlusion and the non-contrast CT scan does not show corresponding early ischemic changes, these patients get transferred specifically to a comprehensive stroke center for consideration of thrombectomy. At our centers, some of these patients get directly transported to the neuro-angio suite for further imaging and possible thrombectomy. Thus, the MSU serve a very important goal of expediting critical neurological care for a stroke patient, not only by administering IV alteplase in the field to qualifying patients, but also early triage and transport of qualifying patients to the neuro-angio-suite and with earlier activation of neuroangiosuite. Dr. Negar Asdaghi:         Perfect, Nirav. An important and a growing concept, bringing treatment to patients and helping with triaging them appropriately, as you mentioned, which I'm sure we'll see more of in the United States and across the world. Now, Diogo, over to you. Can you tell us about the FAST-ED score, its components, then about the reliability of FAST-ED score in the prehospital setting prior to your current study? Dr. Diogo Haussen:         So, the landmark trials published in 2015 defined mechanical thrombectomy as this very effective and powerful treatment of large vessel occlusion stroke patients, and the clinical and the public health impact of this treatment are certainly highly dependent on the rapid triage of these folks into the appropriate destination. So, this involves the prompt identification of patients with severe symptoms by the emergency medical system personnel, and obviously the transportation of them for a thrombectomy capable center. So, some scales had been proposed earlier on, and the FAST-ED was then developed, and it aimed to help with the identification of patients with a higher probability of having a large vessel occlusion stroke. So, in 2017, we validated the scale on stroke patients that had undergone contrast-enhanced vascular images, which had not been done before, in this publication led by Fabricio Lima and Raul Nogueira in Stroke, in the Stroke journal. Dr. Diogo Haussen:         So, this paper demonstrated that FAST-ED had higher accuracy than RACE and CPSS. The main limitation at the time was the fact that the FAST-ED score derived from the NIH Stroke Scale and, therefore, had to be validated in the field. The FAST-ED scale stands for the important features that are involved with stroke care and recognition and triage, such as facial palsy, arm weakness, speech changes, and time. Then we complimented this with findings of critical dysfunction illustrated by eye deviation and also denial/neglect. So, the FAST-ED has the following scoring system: So, facial palsy scored from zero to one; arm weakness from zero to two; speech changes, which is aphasia, from zero to two; time is just for documentation, but not for really any decision-making in terms of the scale itself. So, eye deviation goes from zero to two, and denial/neglect from zero to two, and again, was designed based on the items of the NIH Stroke Scale with higher predictive value for large vessel occlusion strokes. I think Nirav is going to discuss a little bit more about why we chose those cutoffs, but they're all designed in a specific way. Dr. Negar Asdaghi:         Perfect. So a quick score that can be administered easily by different healthcare personnel. So, please tell us, before we go back to Nirav, about your paper's methodology. What were you hoping to expand on the existing knowledge with this paper? Dr. Diogo Haussen:         I'm just going to repeat a few things, but our mobile stroke unit is equipped obviously with a CT machine and is staffed by an EMT driver and emergency medicine registered nurse, a paramedic, and a CT technician. So, a remote evaluation of patients by a vascular neurologist is then performed through this video-based telemedicine platform. The MSU, as he mentioned, is routinely accompanied by an Advanced Life Support–staffed ambulance, which responds to the suspected stroke calls, and sometimes then calls in or calls off the potential of our stroke code. And as part of this MSU evaluation, the FAST-ED is then administered by the MSU paramedic via the FAST-ED smartphone application that was designed. And then an independent NIH is performed by the registered nurse within the MSU. So, subsequently, the patient is transferred into the MSU itself and a non-conscious CT is performed. Once the scan is completed, the patient is evaluated by the vascular neurologist in a two-way video conference where the FAST-ED is then estimated by the physician. Dr. Diogo Haussen:         So, all patients are then transferred to the comprehensive stroke center, where further evaluation, including vascular imaging, is performed. The vascular imaging data was formerly read by neuroradiology and then followed by an independent read by the vascular neurologist for the identification of large vessel occlusion strokes, which we define in this paper as an intracranial occlusion off the internal carotid, the M1 or the M2 branches of the middle cerebral artery or the basilar artery. The study encompassed our initial experience, which was from May of 2018 till August of 2019. And we have some other goals, but the initial experience was planned to allow us to investigate, once again, this most important feature, which is the potential reliability of the estimation of the FAST-ED score by paramedics in the field. Dr. Negar Asdaghi:         Perfect. Thank you for this background, Diogo. Now Nirav, we're ready to hear about the study results. Dr. Nirav Bhatt:               So, in the first 15 months of operation of the mobile stroke unit, we analyzed data on 173 eligible patients. We had an almost equal distribution of our patients in terms of gender. We had 52.6% females, and the majority of our patients were Black. We found that FAST-ED scores matched perfectly between paramedics and vascular neurologists 56% of the time, and there was only a zero to one point difference in 91% of the cases. Cases in which the discrepancy of the FAST-ED score between the paramedic and vascular neurologist was two points or higher were less than 9%. Overall, the intraclass correlation of FAST-ED score between the paramedic and the vascular neurologist was 0.94, indicating excellent interrater reliability. Dr. Negar Asdaghi:         Thank you. You found a higher interrater reliability between the paramedics and vascular neurologists for scores of three or above on the FAST-ED scale. Higher FAST-ED scales also were more specific in terms of detection of a target vessel occlusion. How should your results be interpreted in our day-to-day practice, Nirav? Dr. Nirav Bhatt:               That is correct. When vascular neurologists recorded a FAST-ED score greater than or equal to three, paramedics also recorded a FAST-ED score greater than or equal to three in 87.5% of the instances, and when a vascular neurologist recorded a FAST-ED score of greater than or equal to four, the paramedics also recorded a FAST-ED score of greater than or equal to four in 92% of the instances. This is suggestive that when the patients presented with a moderate to a severe stroke, that EMS paramedics were highly reliable in identifying the neurological severity of these patients. This provides a sound basis for more widespread utilization of FAST-ED as a simple and reliable tool that can be utilized by paramedics to identify stroke severity in the field. Dr. Negar Asdaghi:         Thank you, Nirav. Simple indeed. I know Diogo briefly alluded to this, but can you also tell us a little more about how FAST-ED compares to the other prehospital scoring systems in terms of their interrater reliability and LVO prediction? And what should be our takeaway message from your paper? Dr. Nirav Bhatt:               Yes, absolutely. So, just to give you an example, the Los Angeles Motor Scale, LAMS, tests for facial droop, arm drift, and grip strength, but does not really test for cortical signs. We know that a lot of patients with subcortical strokes will have those features, meaning facial droop, arm drift, and decreased grip strength. Similarly, while RACE is very similar to FAST-ED, it tests for leg weakness in addition to what FAST-ED does. It also puts a lot more emphasis on the facial droop as compared to FAST-ED. And with that, I want to draw your attention to a study that we cited in our paper where these scales were compared head to head, and while the accuracies of all the prehospital scales were found to be acceptable, the accuracy of RACE and LAMS were slightly higher than that of FAST-ED. However, it should be noted that in almost 35% of the cases, a complete FAST-ED score could not be reconstructed largely due to data and availability regarding patients' neglect. Dr. Nirav Bhatt:               This percentage for data and availability for RACE was even higher, meaning we have to consider the feasibility of these scales when we recommend the widespread adoption of these scales into our communities. Overall, the takeaway from this entire study is we strongly believe that there needs to be a system in place for prehospital stroke triage in order to identify and transport the patients to the right destination rapidly. However, the choice of individual scales should be made after consideration of the geographical characteristics of a particular community, and also that experience and that comfort with the level of training required for reliable performance of each of these scales by the EMS personnel. Dr. Negar Asdaghi:         Thank you so much, Nirav. More to come on this, I'm sure, in the future. Thank you for joining us on the podcast today. Dr. Nirav Bhatt:               Thank you so much. It was our pleasure. Dr. Negar Asdaghi:         Thank you, Drs. Nirav Bhatt and Diogo Haussen. Thank you for joining us on the podcast today, and we look forward to covering more of your work in the future. This concludes our podcast for the August 2021 issue of Stroke. Please be sure to check out the August table of contents for the full list of publications, including a special report on the safety of the mobile stroke units and a descriptive review of the amount of radiation exposure to the public, patients, and staff from these mobile units. With that, as our work to save every brain cell from ischemic and hemorrhagic damage continues, we invite you to stay alert with Stroke Alert. Dr. Negar Asdaghi: This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: https://www.catalysthealthtech.com/ (CLICK HERE) --- Driven by a relentless passion for improving patient care via the convergence of biology and technology, our next has dedicated himself to curating global communities that are positively moving industry forward.  Dr. Amir Kalali, Co-Chair of the Decentralized Trials and Research Alliance, and Chairman and Chief Curator of the CNS Summit, joins us to discuss his storied career of leading global drug development and health care services in the neuroscience industry and how his experiences have propelled his passion for convening other industry-leading pioneers to improve patient care.  Join us for this action-packed conversation and call-to-action as we continue to work together to move the healthcare industry forward. Let's go!  Episode Highlights: Dr. Kalali's storied career and globally leading initiatives Why Dr. Kalali has dedicated himself to curating communities to move healthcare forward  How to get involved in Dr. Kalali's initiatives About our Guest:  Dr. Kalali is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is a board director of both private and publicly traded companies, and advises companies in the life sciences and technology sectors, universities and investment groups. Dr. Kalali is the Co-Chair of the Decentralized Trials and Research Alliance (DTRA), Chairman and Chief Curator of the CNS Summit, a forum focused on the future of life sciences, and was the Founding Chairman, and sits on the Executive Committee of the International Society for CNS Drug Development (ISCDD), one of the first independent non-profits to bring together leaders in drug development to collaborate, and on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM). He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development., published by Cambridge University Press. He has authored over 250 peer-reviewed publications, and numerous book chapters. He has been involved in initiatives by the Institute of Medicine, as well as the NIH FAST and the NIH NCATS programs. Previously, for almost 20 years, he was the Global Head of the Neuroscience Center of Excellence at Quintiles, now known as IQVIA. In this role, he led the enterprise-wide strategy for neuroscience, encompassing drug development and health care services. He was responsible for numerous successful drug development programs that have led to dozens of approved new treatments for patients. Dr. Kalali regularly speaks at national and international scientific meetings on topics including drug development, clinical trials, innovation, technology, digital medicine, biohacking, and health. Dr. Kalali's contributions have been recognized by life sciences media including The Medicine Maker's Power List and the PharmaVOICE magazine's Inaugural Red Jacket award, recognizing those who have been most lauded by their peers. Links Supporting This Episode: CNS Summit website: https://cnssummit.org/ (CLICK HERE) DTRA website: https://dtra.org/ (CLICK HERE) Dr. Amir Kalali LinkedIn page: https://www.linkedin.com/in/amirkalali/ (CLICK HERE) Dr. Amir Kalali Twitter page: https://twitter.com/akalali (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest... Support this podcast

How can our kids on the spectrum sleep better? Dr. Mimi Avendano, neuro-developmental pediatrician and Head of the NeuroScience Center of the Philippine Children's Medical Center responds. ASP Ask the Experts podcasts are short, practical advice for Filipinos on the spectrum and those who love and care for them. #AutismOKPH

Alzheimer’s Speaks Radio has partnered with the RSVL A/D to provide resource information for caregivers and people living with dementia during the pandemic. This is our 2nd series on the topic of caring and coping during the pandemic. Dementia Research during the Pandemic - COVID and Cognition Our guest today on Alzheimer's Speaks Radio is William H. Frey II, Ph.D. who is the Senior Research Director in the Center for Memory and Aging at the HealthPartners Neuroscience Center. He start with a presentation on the intranasal method for bypassing the blood-brain barrier to treat neurological disorders while reducing unwanted side effects and we wrap up with questions. Center for Memory & Aging - HealthPartners Neuroscience Center     Alzheimer’s Research Center      Email Link to 1st series of caring and coping during the pandemic Contact Roseville Alzheimer’s and Dementia Community Action Team: Website     Email Contact our Host Lori La Bey  Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world since 2011.

Dr Celia McIntosh is a nurse practioner, speaker, author and Human Trafficking Awareness Educator. Join us for this one of a kind interview with this phenomenal nurse. Dr. Celia McIntosh DNP, RN, FNP-C, PMHNP-BC, SCRN, CEN, CCRN, CNRN is the President of the Rochester Regional Coalition Against Human Trafficking (RRCAHT) and a Nurse Practitioner in the Neuroscience Center at Rochester Regional Health in Rochester, NY. Celia received her associate's in nursing from Monroe Community College, a bachelor's degree in nursing from Brockport State University and her master's degree in nursing, and her Doctorate of Nursing Practice degree from St. John Fisher College. Professionally, Celia has worked as a nurse for a number of organizations, including the Rochester General Hospital and Highland Hospital. She has worked as a family nurse practitioner in the Department of Neuroscience and the Medical Observational Unit Rochester Regional Health System. Celia is an inspiring leader in the Rochester community both in her professional work and her commitment to educating the public about the ubiquity of human trafficking. Celia combines her medical training with her commitment to raising awareness about trafficking victims through the development of educational programs for Health Care Professionals. She presented “Human Trafficking 101: For Emergency Medicine Providers” at Rochester General Hospital's Best Practices Seminar, the Genesee Valley Chapter Emergency Nurses Association, and URMC Anti-Human Trafficking Conference. Most recently, she presented the “Human Trafficking: Globally, Locally and its Impact on Human Rights” at the United Nations Association of Rochester, “Sexual Health: Sex Trafficking Violence and the Pandemic” for the CEI Sexual Health Center of Excellence, on a panel for the Wyoming County Safe Harbour Summit, and the 7th Judicial District Statewide Human Trafficking Intervention Court Web Series. Celia is passionate about ending human trafficking and becoming a voice for policy and social change in the fight against human trafficking.

Intranasal delivery of agents to the brain, Adult stems cells and Insulin for treatment of brain injury and degenerative diseases, Possible effects of COVID-19 on the brain, long term complications, and policy choices. Dr. William H. Frey II is a Senior Research Director of the Center for Memory & Aging at the HealthPartners Neuroscience Center in St. Paul, Minnesota. Dr. Frey’s focus has been the use of a non-invasive intranasal method for bypassing the blood-brain barrier to target therapeutic agents to the brain to treat neurological and psychiatric disorders while reducing unwanted side effects. These conditions include Mild Cognitive Impairment, Stroke, Traumatic Brain Injury, Posttraumatic Stress Disorder, Multiple Sclerosis, Alzheimer's, Parkinson's disease, and other brain diseases. He is also a faculty member in the Graduate Program in Neuroscience at the University of Minnesota. He can be reached at neuroresearch@healthpartners.com / 651-254-3736 --- Send in a voice message: https://anchor.fm/scientificsense/message Support this podcast: https://anchor.fm/scientificsense/support

Dr. William Frey, Senior Research Director, Center for Memory and Aging, HealthPartners Neuroscience Center shares his insights about delivering therapeutic agents to the brain by-passing the blood-brain barrier.  Based on an unusual dream he had in 1989, Bill has been on the path to discover and patent a noninvasive intranasal method of delivering drugs to the brain to treat Alzheimer's and other brain disorders.  Bill also warns that we should be looking at how COVID-19 is reaching the brain and any long-term impact the virus might have. Center for Memory and Aging Listen to the podcast here

Dr. William Frey, Senior Research Director, Center for Memory and Aging, HealthPartners Neuroscience Center shares his insights about delivering therapeutic agents to the brain by-passing the blood-brain barrier.  Based on an unusual dream he had in 1989, Bill has been on the path to discover and patent a noninvasive intranasal method of delivering drugs to the brain to treat Alzheimer's and other brain disorders.  Bill also warns that we should be looking at how COVID-19 is reaching the brain and any long-term impact the virus might have. Center for Memory and Aging Download the transcript here

On this episode 39 of the Chicago Psychology Podcast Dr.Hoye is joined by Cindy and Melanie Dillon, a licensed, clinical professional counselor. Cindy and Melanie discuss their work with ketamine therapists at the Neuroscience Center in Deerfield, IL. We dive deep into the process of ketamine assisted therapy, the comprehensive, integrative program at the Neuroscience Center, the center’s use of transcranial magnetic stimulation therapy with ketamine, and cannabis therapy. It’s a discussion with two experts who are dedicated to the integration of new therapies with psychotherapy to assist people with intractable, long-standing psychiatric issues. The Neuroscience Center Website The Ketamine Papers

Helen M. Genova, Ph.D. is the assistant director of Kessler Foundation's Center for Neuropsychology and Neuroscience Research. She is also an assistant research professor in the Department of Physical Medicine and Rehabilitation at Rutgers University-NJ Medical School. She has focused on examining cognitive issues in clinical populations, including those utilizing both behavioral and neuroimaging methods to study social cognition and emotional processing. Particularly in regard to social cognition, Dr. Genova has played an important role in pioneering innovative research applying promising interventions targeting deficits in social cognition. Dr. Genova has also devoted much of her career to investigating other cognitive issues in clinical populations, including the assessment and treatment of cognitive fatigue. View the podcast transcript at https://kesslerfoundation.org/sites/default/files/2019-11/Helen-Genova-on-Cognitive-Issue-in-the-Brain-Expert-Interview-Series.pdf More about Dr. Genova and her research (https://kesslerfoundation.org/aboutus/Helen%20Genova?utm_source=soundcloud&utm_medium=podcast&utm_term=&utm_content=bio%20link&utm_campaign=genova) Center for Neuropsychology and Neuroscience(Center for Neuropsychology and Neuroscience) Join a study (https://kesslerfoundation.org/join-our-research-studies?utm_source=soundcloud&utm_medium=podcast&utm_term=&utm_content=join%20a%20study&utm_campaign=genova)

My guest this week is Dr. Silvana Costa, a research scientist in the Neuropsychology and Neuroscience Center at the Kessler Foundation. Dr. Costa's work is focused on cognitive impairment in MS, specifically, information processing speed, which is something that people living with MS often have to deal with. We'll talk with Dr. Costa about some of her specific research, along with a promising intervention designed to improve cognitive processing speed for people living with MS.      We're also talking about the FDA approval of Vumerity, an oral disease-modifying therapy for relapsing-remitting MS and active secondary progressive MS. We'll tell you about the stem cell therapy that was just approved for people with MS in Scotland.   The Patient-Centered Outcomes Research Institute is an important part of the Affordable Care Act. It's currently authorized to operate for just 16 more days. You'll learn about the bipartisan effort in the U.S. Congress to re-authorize PCORI, and why that benefits people affected by MS.   November is National Family Caregivers Month, and we're talking about what that means, why it's important, and why MS caregivers need to #BeCareCurious.   We have a lot to talk about! Are you ready for RealTalk MS??! ___________   Let's Meet Up! Where I'll Be in November  :22 Vumerity Receives FDA Approval  3:44 Patient-Centered Outcomes Research Institute (PCORI) Bipartisan Re-Authorization Bill  4:34 Hematopoietic Stem Cell Transplantation (HSCT) Approved for MS in Scotland   8:38 November is National Family Caregivers Month  10:42 My Interview with Dr. Silvana Costa  15:53 How to Subscribe to RealTalk MS, Download the RealTalk MS App, or Listen with Alexa  24:19 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Give RealTalk MS a Rating & Review  Kessler Foundation Patient-Centered Outcomes Research Institute iConquer MS Caregiver Action Network -- National Family Caregivers Month Give RealTalk MS a Rating & Review  Download the RealTalk MS App for iOS Download the RealTalk MS App for Android ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 114 Hosted By: Jon Strum Guests: Dr. Silvana Costa Tags: MS, MultipleSclerosis, MSResearch, MSSociety, PCORI, stemcells, BeCareCurious, KesslerFdn, RealTalkMS

What does depression do to our brain and can antidepressants help? This topic, abound with misconceptions and controversy, is becoming more relevant as depressive disorder climbs on the list of greatest health burdens.To find out what current research is showing, Kim and Alessia talk to Eero Castren, a professor at the University of Helsinki and a principal investigator at the Neuroscience Center there. A trained medical doctor with a PhD in neuropharmacology, our guest has a remarkable resume as a researcher, including work with Bethesda National Institute of Mental Health, Columbia University, and Max Planck Institute. His main area of expertise are neurotrophic factors - biomolecules that make neural connections possible. “Neurons,” Castren explains, “do not work alone, but as a network”, and neurotrophic factors allow establishment, maintenance, and, eventually, change of neural networks. These networks, in turn, represent all the things in our memory. Neurotrophic factors are, therefore, essential to the ability to learn and evolve - brain plasticity or neuroplasticity. In this talk, Castren pays special attention to the effects of depression on neuroplasticity, especially on BDNF - a particularly important factor. He discusses findings on antidepressants and provides some advice on how to fight depression. Besides depression treatment, Castren also tackles new developments in treatment of Alzheimer’s and Parkinson’s disease, as well as stroke. Non-patients are not forgotten - our guest tells us about how to keep our brains plastic and make memory stronger. Kim Baden-Kristensen is the co-founder and CEO of Brain+, a digital therapeutics company that helps people with brain disorders and injuries to recover their fundamental cognitive brain functions and daily life capabilities by using an app-based cognitive rehabilitation platform, which is developed in close collaboration with patients, clinicians and researchers.https://www.linkedin.com/in/kbadenk/ Alessia Covello is a life science IT consultant working in the field of healthcare technology implementation, and advocating for better services for people with brain conditions and learning disabilities.https://www.linkedin.com/in/alessiacovello/ Topics discussed:4:57 - What are neurotrophic factors? How are they relevant for learning?13:00 - Neuroplasticity and age15:37 - TIPS: Can we influence the activity of neurotrophic factors and how?19:38 - New treatments for Huntington’s disease, Alzheimer’s dementia, and Parkinson’s disease23:34 - Causes of deficiency in neurotrophic factors - genetic and other26:40 - Drugs that stimulate production of BDNF - study of antidepressants36:08 - TIPS: How to make depression treatment truly effective? Advice on physical activity and other ways to deal with depression41:45 - Brain plasticity and depression43:50 - Other uses of antidepressants (e.g. stroke)45:38 - Common misconceptions about antidepressants48:30 - Take home messagesDisclaimer:All references to products, companies, and organizations in this podcast and the article that accompanies it are included with the purpose to

This episode is all about neuronal apoptosis.  In Dr. Mohanish Deshmukh's eyes, some cells are willing to undergo apoptosis, while others are very cautious.  Understanding these differences could be the key to understanding, treating, or curing diseases that haunt us in modern times.  Research in Dr. Deshmukh’s lab at the University of North Carolina, Chapel Hill, focuses on pathways for neuronal apoptosis and the ways that survival and death work in different cells. Apoptosis is programmed cell death.  In apoptosis, cells commit "suicide" quietly to minimize inflammation and damage to their neighbors.  Apoptosis is a normal and vital process which helps protect us from cancer and other disease states.  However, it becomes a problem in neurodegenerative diseases like Alzheimer's and ALS.  When it comes to apoptosis, neurons are special.  Neuronal apoptosis seems to be distinct from other cell types. Listen in to hear how neurons resist triggers that would kill other cells.  Also learn about the difference between apoptosis and necrosis, as well as how that understanding has changed over time.  We discuss the importance of synaptic pruning.  Finally, we speculate some on the possible presence and effect of bacteria in the brain. About Dr. Deshmukh Dr. Mohanish Deshmukh is a Professor of Cell Biology & Physiology and the Neuroscience Center at the University of North Carolina, Chapel Hill.  Visit the Deshmukh Lab website to learn more about current research. Also follow the Deshmukh Lab on Instagram. More Information To get a background of apoptosis in other cells, check out Episode 23: The Role of Apoptosis with Georgia Smith.  She tells us about apoptosis in the context of influenza.   Any other questions?  Let us know!  We appreciate your feedback. You can now support the podcast at https://www.patreon.com/sfspodcast.  Many thanks to our past and present supporters!  Thanks to Plant Warrior for their support.  Use discount code SFS10 at checkout for 10% off your purchase of plant-based protein.

Dr. Amir Kalali is a highly respected member of the global community in life sciences and clinical research. In fact, for 5 of the years between 2005 and 2012, PharmaVOICE magazine named him as one its 100 most inspiring leaders in the life sciences as voted by his peers. Dr. Kalali was Global Head of the Neuroscience Center of Excellence at Quintiles IMS. He was responsible for the enterprise-wide [...] Get all the show notes by visiting DigitalHealthToday.com/60 This episode is made possible by Medable. Medable enables mobile solutions to globalize clinical research with anytime, anywhere participant data capture through connected devices. Learn more at medable.com and get a demo today. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, the Editor-in-Chief of JNIS Felipe Albuquerque speaks to Raul Nogueira (Department of Neurology, Emory University School of Medicine/Marcus Stroke & Neuroscience Center, Atlanta, Georgia, USA). He is the co-author of the study "Too good to intervene? Thrombectomy for large vessel occlusion strokes with minimal symptoms: an intention-to-treat analysis". Read the full paper published in the October 2017 issue of the journal also on the JNIS website: http://dx.doi.org/10.1136/neurintsurg-2016-012633. The second article mentioned in this podcast, "Thrombectomy versus medical management for large vessel occlusion strokes with minimal symptoms: an analysis from STOPStroke and GESTOR cohorts", can be found here: http://dx.doi.org/10.1136/neurintsurg-2017-013243.

In this podcast, Italo Linfante, Miami Cardiac and Vascular Institute and Neuroscience Center, Baptist Hospital, Miami, USA, tells JNIS’ Editor Robert Tarr, the details of his study “Predictors of poor outcome despite recanalization: a multiple regression analysis of the NASA registry”. To access the full article, click here: http://goo.gl/wNEljN .

Video 1 Preview Image Caption